- BiomX (PHGE, Financial) reports positive Phase 2 trial results for BX211 in treating diabetic foot osteomyelitis, with statistically significant improvements in ulcer metrics.
- The company secured $40 million in non-dilutive funding from the U.S. Defense Health Agency for BX211's development.
- BiomX's cash position increased to $21.2 million with financial stability projected into Q1 2026, despite a net loss reduction to $7.7 million.
BiomX Inc. (PHGE) has announced significant advancements in the first quarter of 2025, particularly focusing on its clinical programs. A noteworthy achievement was the positive Phase 2 trial outcomes for BX211, aimed at treating diabetic foot osteomyelitis (DFO). The trial revealed statistically significant improvements in ulcer size and depth reduction compared to placebo, establishing BX211 as an effective treatment solution. The company continues to receive substantial backing with a $40 million non-dilutive funding from the U.S. Defense Health Agency.
Furthermore, the BX004 Phase 2b study targeting cystic fibrosis is progressing as planned, with topline results anticipated in Q1 2026. Recent shareholder approval for warrant exercises, part of $12 million in financing announced in February 2025, is expected to extend BiomX's operational runway through these critical developmental phases.
Financially, BiomX ended Q1 2025 with a cash balance of $21.2 million, up from $18.0 million at the end of 2024. The quarter's results indicate a net loss of $7.7 million, a significant improvement from the $17.3 million loss in Q1 2024. The increase in research and development expenses from $4.1 million to $5.3 million reflects ongoing investments in the company's pipeline advancements. As BiomX prepares for further developments, it positions itself strategically for upcoming milestones in its phage therapy platform.
